I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual MeetingPRNewsWire • 03/09/22
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric CancerPRNewsWire • 03/03/22
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics DrugsPRNewsWire • 01/28/22
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid TumorsPRNewsWire • 01/18/22
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid TumorsPRNewsWire • 01/12/22
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid TumorsPRNewsWire • 12/27/21
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards CommercializationPRNewsWire • 12/20/21
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in ChinaPRNewsWire • 12/15/21
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021PRNewsWire • 12/14/21
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's LymphomaPRNewsWire • 12/09/21
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's DiseasePRNewsWire • 12/08/21
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong LimitedPRNewsWire • 12/07/21
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid TumorsPRNewsWire • 12/03/21
Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?Zacks Investment Research • 11/17/21
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin AlfaPRNewsWire • 11/10/21
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITCPRNewsWire • 11/09/21
I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIEPRNewsWire • 11/08/21
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021PRNewsWire • 11/04/21